LSFV-IL12

LSFV-IL12 appears to be a code name for an investigational drug candidate based on interleukin 12 (IL-12), a heterodimeric cytokine with potent immunostimulatory and anti-tumor properties. IL-12 is primarily produced by antigen-presenting cells and acts as a bridge between innate and adaptive immunity. It induces interferon-gamma (IFN-γ) production, promotes natural killer (NK) cell cytotoxicity, enhances T cell responses, facilitates the differentiation of naïve CD4+ T cells into Th1 cells, and promotes B cell maturation into IgM-secreting plasma cells[1][4][5]. These immune-modulating effects make IL-12 an attractive candidate for cancer immunotherapy. However, systemic administration of IL-12 has been limited by dose-limiting toxicities; thus, various strategies—including fusion proteins or localized delivery—are under investigation to improve its safety profile[2][3][6]. The specific details about the structure or unique features of LSFV-IL12 are not available in the provided sources.